PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis
- PMID: 27535340
- PMCID: PMC4992158
- DOI: 10.1038/ncomms12502
PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis
Abstract
Fibrosis due to extracellular matrix (ECM) secretion from myofibroblasts complicates many chronic liver diseases causing scarring and organ failure. Integrin-dependent interaction with scar ECM promotes pro-fibrotic features. However, the pathological intracellular mechanism in liver myofibroblasts is not completely understood, and further insight could enable therapeutic efforts to reverse fibrosis. Here, we show that integrin beta-1, capable of binding integrin alpha-11, regulates the pro-fibrotic phenotype of myofibroblasts. Integrin beta-1 expression is upregulated in pro-fibrotic myofibroblasts in vivo and is required in vitro for production of fibrotic ECM components, myofibroblast proliferation, migration and contraction. Serine/threonine-protein kinase proteins, also known as P21-activated kinase (PAK), and the mechanosensitive factor, Yes-associated protein 1 (YAP-1) are core mediators of pro-fibrotic integrin beta-1 signalling, with YAP-1 capable of perpetuating integrin beta-1 expression. Pharmacological inhibition of either pathway in vivo attenuates liver fibrosis. PAK protein inhibition, in particular, markedly inactivates the pro-fibrotic myofibroblast phenotype, limits scarring from different hepatic insults and represents a new tractable therapeutic target for treating liver fibrosis.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4992158/bin/ncomms12502-f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4992158/bin/ncomms12502-f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4992158/bin/ncomms12502-f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4992158/bin/ncomms12502-f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4992158/bin/ncomms12502-f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4992158/bin/ncomms12502-f6.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4992158/bin/ncomms12502-f7.gif)
Similar articles
-
Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling.Phytomedicine. 2020 Nov;78:153294. doi: 10.1016/j.phymed.2020.153294. Epub 2020 Jul 28. Phytomedicine. 2020. PMID: 32771890
-
ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis.Int J Mol Sci. 2019 Jun 1;20(11):2700. doi: 10.3390/ijms20112700. Int J Mol Sci. 2019. PMID: 31159366 Free PMC article. Review.
-
Hedgehog-YAP Signaling Pathway Regulates Glutaminolysis to Control Activation of Hepatic Stellate Cells.Gastroenterology. 2018 Apr;154(5):1465-1479.e13. doi: 10.1053/j.gastro.2017.12.022. Epub 2018 Jan 3. Gastroenterology. 2018. PMID: 29305935 Free PMC article.
-
Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases.Exp Mol Med. 2017 Nov 17;49(11):e396. doi: 10.1038/emm.2017.213. Exp Mol Med. 2017. PMID: 29147013 Free PMC article.
-
The origin of fibrogenic myofibroblasts in fibrotic liver.Hepatology. 2017 Mar;65(3):1039-1043. doi: 10.1002/hep.28948. Epub 2017 Jan 11. Hepatology. 2017. PMID: 27859502 Free PMC article. Review.
Cited by
-
Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer.Nat Commun. 2024 Apr 1;15(1):2806. doi: 10.1038/s41467-024-47068-z. Nat Commun. 2024. PMID: 38561380 Free PMC article.
-
Mechanisms of norcantharidin against renal tubulointerstitial fibrosis.Pharmacol Rep. 2024 Apr;76(2):263-272. doi: 10.1007/s43440-024-00578-5. Epub 2024 Mar 12. Pharmacol Rep. 2024. PMID: 38472637 Review.
-
SPP2 plays a role in the tumorigenesis of hepatocellular carcinoma: A bioinformatic based analysis.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Dec 28;48(12):1779-1792. doi: 10.11817/j.issn.1672-7347.2023.230077. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 38448371 Free PMC article.
-
PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response.Cells. 2023 Nov 23;12(23):2692. doi: 10.3390/cells12232692. Cells. 2023. PMID: 38067120 Free PMC article. Review.
-
Mechanobiology of portal hypertension.JHEP Rep. 2023 Aug 2;5(11):100869. doi: 10.1016/j.jhepr.2023.100869. eCollection 2023 Nov. JHEP Rep. 2023. PMID: 37841641 Free PMC article. Review.
References
-
- Ellis E. L. & Mann D. A. Clinical evidence for the regression of liver fibrosis. J. Hepatol. 56, 1171–1180. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials